It should be noted that none of the 9 patients with a BRAF-mutant tumour responded to cetuximab, whereas objective responses occurred in 14 of 83 (17%) patients whose tumours carried WT BRAF alleles. The gene discussed is BRAF; the disease is neoplasm.